Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 7/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | CYBB | P04839 | 1/20 | 0.41 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21537936 | 0.94 | DGAT1 (0.45) | DGAT1ABCC1ABCG2ABCB1NCF1 | |
| SCHEMBL13139277 | 0.92 | MMP2 (0.47) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL16180807 | 0.92 | MMP2 (0.47) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL24276657 | 0.91 | DGAT1 (0.53) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL18768971 | 0.91 | DGAT1 (0.53) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL24450930 | 0.89 | DGAT1 (0.39) | DGAT1ABCB1NCF1MMP2MMP9 | |
| SCHEMBL24276659 | 0.89 | DGAT1 (0.43) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21118075 | 0.89 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL21118027 | 0.89 | DGAT1 (0.52) | DGAT1 | |
| SCHEMBL27269271 | 0.87 | GBA1 (0.39) | DGAT1ABCB1NCF1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| WO-2016081670-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | DGAT1 1239/4885ABCC1 2642/4885ABCG2 2508/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | DGAT1 1239/4885ABCC1 2642/4885ABCG2 2508/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | DGAT1 1239/4885ABCC1 2642/4885ABCG2 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.